The Latest Breaking News from VERV

Cathie Wood's flagship Ark Innovation ETF ARKK just had its best week ever thanks to Roku, DraftKings, Palantir and other huge winners on big news.

Lilly will pay $250 million to Beam for the rights to three gene-editing drugs from Verve. VERV stock and Beam stock skyrocketed.

U.S. stocks traded higher midway through trading, with the Dow Jones gaining more than 200 points on Monday.

U.S. officials halted Verve's plan to begin testing in people a gene-editing approach to high cholesterol, leading VERV stock to crash.

Verve Therapeutics announced disappointing lab results for its CRISPR gene-editing approach to high cholesterol, and VERV stock skidded.

With the Fed seemingly yet to be done with aggressive rate hikes to control sky-high inflation, troubles for Cathie Wood’s fleet of ETFs seem far from over. Due to overexposure to disruptive, tech-oriented businesses and cash-guzzling businesses, her investments' near-term outlook appears bleak. Hence, fundamentally weak Cathie Wood holdings Ui…

Cathie Wood’s ETFs performed miserably this year amid a market rout caused by soaring inflation, the Fed’s aggressive rate hikes, and rising odds of a recession. More trouble awaits her hedge fund, concentrated in tech, as September job gains almost affirm another aggressive rate hike in the Fed’s next meeting.…

Cathie Wood’s ETFs have hit a rough patch this year amid volatile market conditions caused by sky-high inflation and the Fed’s hawkish tilt. Moreover, the stock market is expected to remain under pressure in the coming months since the central bank intends to keep hiking rates. So, we think it…

Investors’ sentiment is significantly mixed at the moment, with market volatility at its peak. It could be wise to buy quality stock Vertex Pharmaceuticals (VRTX), which possesses robust financials. However, fundamentally weak stock NeoGenomics (NEO) is best avoided now. Read on….